Prana raises $5m from institutional investors
Monday, 08 September, 2003
Joining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.
According to CEO Geoffrey Kempler, the placement demonstrates a vote of confidence in the company by investors, and increased understanding of what Prana is trying to achieve.
The funds raised will be used to accelerate the pre-clinical development of the company's lead compound PBT-2 as a therapeutic for Alzheimer's disease. The drug was recently selected from a library of around 300 metal protein attenuating compounds (MPACs) to advance through to clinical trials, and in pre-clinical studies has outperformed PBT-1 (clioquinol), an existing off-label drug that has been successfully tested in proof-of-concept human studies.
"If all goes well, we would like to see Phase I trials start before the end of 2004, probably in the third quarter," said Kempler.
With existing cash, he said, the company had more than $7 million in the bank, enough for at least the next 18 months. Prana also has a milestone-based agreement in place with pharmaceutical company Schering, which will provide $7.3 million in R&D funding plus milestone payments and potentially royalties over the next few years towards new research targets identified by Prana and the development of diagnostics for Alzheimer's disease.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...